Title:
SYNERGISTIC EFFECT BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATE AND PI3K-AKTmTOR PATHWAY INHIBITOR
Document Type and Number:
Japanese Patent JP2019070021
Kind Code:
A
Abstract:
To provide a method for treating cancer in a patient by the combined use of an antibody drug conjugate bound to an anticancer drug and a drug which shows a synergistic effect therewith.SOLUTION: This method of treating cancer comprises the step of administering to the subject an auristatin-based antibody drug complex and a PI3K-AKT-mTOR pathway inhibitor. The auristatin-based antibody drug conjugate preferably has a structure represented by the following formula. [mAb is monoclonal antibody; S is a sulfur atom of antibody; and p is 1 to 8]SELECTED DRAWING: Figure 5
Inventors:
TIMOTHY S LEWIS
LAW CHE-LEUNG
JULIE A MCEARCHERN
LAW CHE-LEUNG
JULIE A MCEARCHERN
Application Number:
JP2019003384A
Publication Date:
May 09, 2019
Filing Date:
January 11, 2019
Export Citation:
Assignee:
SEATTLE GENETICS INC
International Classes:
A61K39/395; A61K31/436; A61K38/05; A61K45/00; A61K47/68; A61P35/00; A61P43/00
Attorney, Agent or Firm:
Yusuke Hiraki
Satoshi Fujita
Natsuo Tanaka
Satoshi Fujita
Natsuo Tanaka